Mild cognitive impairment in patients with Parkinson´s disease and the analysis of associated factors

References

• Saredakis D, Collins-Praino LE, Gutteridge DS, et al. Conversion to MCI and dementia in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2019;65:20–31. doi: 10.1016/j.parkreldis.2019.04.020
   PubMed Web of Science ®Google Scholar
• Schapira AH, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–450. doi: 10.1038/nrn.2017.62
   PubMed Web of Science ®Google Scholar
• Guo Y, Liu FT, Hou XH, et al. Predictors of cognitive impairment in Parkinson’s disease: a systematic review and meta-analysis of prospective cohort studies. J Neurol. 2021;268(8):2713–2722. doi: 10.1007/s00415-020-09757-9
   PubMed Web of Science ®Google Scholar
• Goldman JG, Holden SK, Litvan I, et al. Evolution of diagnostic criteria and assessments for Parkinson’s disease mild cognitive impairment. Mov Disord. 2018;33(4):503–510. doi: 10.1002/mds.27323
   PubMed Web of Science ®Google Scholar
• Compta Y, Martí MJ. Parkinson disease: what goes around comes around: cognitive impairment as prodromal Parkinsonism? Nat Rev Neurol. 2017;13(12):709–710. doi: 10.1038/nrneurol.2017.159
   PubMed Web of Science ®Google Scholar
• Baiano C, Barone P, Trojano L, et al. Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: a meta-analysis. Mov Disord. 2020;35(1):45–54. doi: 10.1002/mds.27902
   PubMed Web of Science ®Google Scholar
• Jones JD, Kuhn TP, Szymkowicz SM. Szymkowicz SM.Reverters from PD-MCI to cognitively intact are at risk for future cognitive impairment: analysis of the PPMI cohort. Park Rel Dis. 2018;47:3–7. doi: 10.1016/j.parkreldis.2017.12.006
   PubMed Web of Science ®Google Scholar
• Pfeiffer HC, Løkkegaard A, Zoetmulder M, et al. Cognitive impairment in early-stage non-demented Parkinson’s disease patients. Acta Neurol Scand. 2014;129(5):307–318. doi: 10.1111/ane.12189
   PubMed Web of Science ®Google Scholar
• Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374:26–31. doi: 10.1016/j.jns.2017.01.012
   PubMed Web of Science ®Google Scholar
• Kandiah N, Mak E, Ng A, et al. Cerebral white matter hyperintensity in Parkinson’s disease: a major risk factor for mild cognitive impairment. Parkinsonism Relat Disord. 2013;19(7):680–683. doi: 10.1016/j.parkreldis.2013.03.008
   PubMed Web of Science ®Google Scholar
• Ham JH, Lee JJ, Sunwoo MK, et al. Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson’s disease. Parkinsonism Relat Disord. 2016;24:95–99. doi: 10.1016/j.parkreldis.2015.12.017
   PubMed Web of Science ®Google Scholar
• Mak E, Dwyer MG, Ramasamy DP, et al. White matter hyperintensities and mild cognitive impairment in Parkinson’s disease. J Neuroimaging. 2015;25(5):754–760. doi: 10.1111/jon.12230
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi: 10.1002/mds.26424
   PubMed Web of Science ®Google Scholar
• Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653. doi: 10.1002/mds.23429
   PubMed Web of Science ®Google Scholar
• Giladi N, Tal J, Azulay T, et al. Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord. 2009;24(5):655–661. doi: 10.1002/mds.21745
   PubMed Web of Science ®Google Scholar
• Güngen C, Ertan T, Eker E, et al. Standardize Mini Mental test’in türk toplumunda hafif demans tanisinda geçerlik ve güvenilirliği [reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population]. Turk Psikiyatri Derg. 2002;13(4):273–281.
   PubMedGoogle Scholar
• Ozdilek B, Kenangil G. Validation of the Turkish version of the Montreal cognitive Assessment scale (MoCA-TR) in patients with Parkinson’s disease. Clin Neuropsychol. 2014;28(2):333–343. doi: 10.1080/13854046.2014.881554
   PubMed Web of Science ®Google Scholar
• Kenangil G, Orken DN, Ur E, et al. Frontal assessment battery in patients with Parkinson disease in a Turkish population. Cogn Behav Neurol. 2010;23(1):26–28. doi: 10.1097/WNN.0b013e3181c5e2b0
   PubMed Web of Science ®Google Scholar
• Romenets SR, Wolfson C, Galatas C, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Park Rel Dis. 2012;18(1):54–58. doi: 10.1016/j.parkreldis.2011.08.013
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kohnen R, Högl B, et al. Parkinson’s disease sleep scale—validation of the revised version PDSS‐2. Mov Disord. 2011;26(4):644–652. doi: 10.1002/mds.23476
   PubMed Web of Science ®Google Scholar
• Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–545. doi: 10.1093/sleep/14.6.540
   PubMed Web of Science ®Google Scholar
• Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh sleep quality index. J Psychosom Res. 1998;45(1):5–13. doi: 10.1016/s0022-3999(97)00298-5
   PubMed Web of Science ®Google Scholar
• Hisli N. Beck Depresyon Envanteri’nin üniversite öğrencileri için geçerliği, güvenirliği. Psikoloji Dergisi. 1989;23:3–13.
   Google Scholar
• Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–356. doi: 10.2214/ajr.149.2.351
   PubMed Web of Science ®Google Scholar
• Nie K, Gao Y, Mei M, et al. The clinical characteristics and cognitive features of mild cognitive impairment in Parkinson’s disease and the analysis of relevant factors. J Clin Neurosci. 2019;63:142–148. doi: 10.1016/j.jocn.2019.01.021
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069. doi: 10.1212/WNL.0b013e3181f39d0e
   PubMed Web of Science ®Google Scholar
• Schrag A, Siddiqui UF, Anastasiou Z, et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol. 2017;16(1):66–75. doi: 10.1016/S1474-4422(16)30328-3
   PubMed Web of Science ®Google Scholar
• Saricaoglu M, Yilmaz NH, Ozer FF, et al. The correlation of non-motor symptoms and sleep on balance in Parkinson’s disease patients with normal cognition and mild cognitive impairment. Ir J Med Sci. 2021;190(4):1577–1584. doi: 10.1007/s11845-020-02462-6
   PubMed Web of Science ®Google Scholar
• Merlino G, Piani A, Gigli GL, et al. Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: a population-based study. Sleep Med. 2010;11(4):372–377. doi: 10.1016/j.sleep.2009.07.018
   PubMed Web of Science ®Google Scholar
• Goldman JG, Ghode RA, Ouyang B, et al. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(9):806–811. doi: 10.1016/j.parkreldis.2013.05.006
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain PE, RB D Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol. 2002;59(6):986–989. doi: 10.1001/archneur.59.6.986
   PubMedGoogle Scholar
• Zhang G, Zhang C, Wang Y, et al. Is hyperhomocysteinemia associated with the structural changes of the substantia nigra in Parkinson’s disease? A two-year follow-up study. Park Rel Dis. 2019;60:46–50. doi: 10.1016/j.parkreldis.2018.10.008
   PubMed Web of Science ®Google Scholar
• Tur EK, Kenangil G, Domaç FM. The relationship between homocysteine concentrations and possible polyneuropathy in early stages of Parkinson disease. Neurol Sci Neurophysiol. 2019;36(4):223–230. doi: 10.5152/NSN.2019.12469
   Web of Science ®Google Scholar
• Song IU, Kim JS, Park IS, et al. Clinical significance of homocysteine (hcy) on dementia in Parkinson’s disease (PD). Arch Gerontol Geriatr. 2013;57(3):288–291. doi: 10.1016/j.archger.2013.04.015
   PubMed Web of Science ®Google Scholar
• Licking N, Murchison C, Cholerton B, et al. Homocysteine and cognitive function in Parkinson’s disease. Parkinsonism Relat Disord. 2017;44:1–5. doi: 10.1016/j.parkreldis.2017.08.005
   PubMed Web of Science ®Google Scholar
• Periñán MT, Macías-García D, Jesús S, et al. Homocysteine levels, genetic background, and cognitive impairment in Parkinson’s disease. J Neurol. 2023;270(1):477–485. doi: 10.1007/s00415-022-11361-y
   PubMed Web of Science ®Google Scholar
• Sampedro F, Martínez-Horta S, Horta-Barba A, et al. Increased homocysteine levels correlate with cortical structural damage in Parkinson’s disease. J Neurol Sci. 2022;434:120148. doi: 10.1016/j.jns.2022.120148
   PubMed Web of Science ®Google Scholar
• Rajagopalan P, Hua X, Toga AW, et al. Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport. 2011;22(8):391–395. doi: 10.1097/WNR.0b013e328346bf85
   PubMed Web of Science ®Google Scholar
• Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, et al. Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov Disord. 2016;31(6):861–881. doi: 10.1002/mds.26662
   PubMed Web of Science ®Google Scholar
• Liu H, Deng B, Xie F, et al. The influence of white matter hyperintensity on cognitive impairment in Parkinson’s disease. Ann Clin Trans Neurol. 2021;8(9):1917–1934. doi: 10.1002/acn3.51429
   PubMed Web of Science ®Google Scholar
• Linortner P, McDaniel C, Shahid M, et al. White matter hyperintensities related to Parkinson’s disease executive function. Mov Disord Clin Pract. 2020;7(6):629–638. doi: 10.1002/mdc3.12956
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li S, Wang S. Application of periventricular white matter hyperintensities combined with homocysteine into predicting mild cognitive impairment in Parkinson’s disease. Int J Gen Med. 2023;16:785–792. doi: 10.2147/IJGM.S399307
   PubMed Web of Science ®Google Scholar
• Oh YS, Kim JS, Lee KS. Orthostatic and supine blood pressures are associated with white matter hyperintensities in Parkinson disease. J Mov Disord. 2013;6(2):23–27. doi: 10.14802/jmd.13006
   PubMedGoogle Scholar